tbuckley/cabot-search huggingface dataset:
THU0458 Investigation of the role of m-tor pathway in kidney needle biopsies of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis
Authors: Z. Soypacaci, O. Cakmak, F. Cakalagaoglu, O. Gercik, I. Ertekin, A. Uzum, R. Ersoy, S. Akar
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) frequently affect the kidneys and renal involvement is an important factor regarding morbidity and mortality. Kidney lesion in AAV is characterised by necrotizing and crescentic glomerulonephritis by little or no immune deposition, and hence it was called pauci-immune glomerulonephritis (PIGN). The underlying mechanisms in the formation or progression of crescent formation need further investigations. Mammalian target of rapamycin (mTOR) is a serine/threonine kinase and plays role in the regulation of cell growth and proliferation. <h3>Objectives</h3> We aimed to evaluate the role of mTOR, which might be a potential therapeutic target, in kidney biopsies of patients with AAV. <h3>Methods</h3> The patients diagnosed as PIGN at an outpatient nephrology clinics of a tertiary hospital, between <sup>May 2009</sup> and June 2016, were retrospectively reviewed and those patients who had a renal biopsy before receiving an immunosuppressive treatment were included in the study. Renal biopsy specimens were immunohistochemically stained with antibodies of mTOR, phosphatase and tensin homolog (PTEN) and transforming growth factor- β (TGF-β) and scored by an experienced renal pathologist. <h3>Results</h3> In total 54 patients with AAV ([52%] female) were included in the study. Twenty-five (46%) patients were diagnosed as granulomatosis with polyangiitis, 6 (11%) patients as microscopic polyangiitis, 16 (30%) patients as renal-limited disease, one (2%) patient as eosinophilic granulomatosis with polyangiitis. Six (11%) patients with PIGN could not be classified definitely. According to the histopathologic examination; 22% of the biopsies were classified as focal, 33% crescentic, 22% mixed and 22% as sclerotic. The mTOR was expressed in substantial percentages of glomeruli of patients with PIGN. However we observed PTEN expression in all samples and mTOR in all tubulointerstitial areas. mTOR expression was found to be related with the presence of crescentic and sclerotic changes observed in glomeruli and the degree of fibrosis in interstitial areas. In our study serum creatinine level or response to treatment were not found to be associated with mTOR pathway expression <h3>Conclusions</h3> Our study showed that glomerular or interstitial expression of PI3K/Akt/mTOR pathway may play a role in the pathogenesis of PIGN and mTORC1 inhibitors might provide a viable alternative for this disease. <h3>Disclosure of Interest</h3> None declared
SAT0436 Transjugular renal biopsy: a safe and effective way to perform renal biopsy in systemic lupus erythematosus and antiphospholipid antibody syndrome patients treated with anti-thrombotic drugs – a monocentric experience of 256 procedures
Authors: H. Nielly, A. Mathian, M. Cazenave, H. Izzedine, J. Haroche, F. Cohen-Aubart, P. Rouvier, I. Brocheriou, P. Cluzel, Z. Amoura
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Renal biopsy is the cornerstone of Lupus nephritis (LN) management. However, transcutaneous renal biopsy (TCRB) is hampered by the antithrombotic treatment frequently prescribed in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Antibody Syndrome (APS). Transjugular renal biopsy (TJRB) offers an attractive alternative for patients at increased risk of bleeding. <h3>Objectives</h3> The primary objective of the study was to describe the safety and the diagnostic performance of TJRB in SLE and APS. <h3>Methods</h3> A retrospective review of SLE and/or APS patients who consecutively underwent a renal biopsy in our department between <sup>January 2004</sup> and October 2016 was performed. Biopsies were divided into four groups: TCRB, TJRB with aspirin treatment (aspirin TJRB), TJRB with anticoagulant treatment (anticoagulant TJRB), and TJRB without anti-thrombotic drug (no-antithrombotic TJRB). Major complications were defined as decease, haemostasis nephrectomy, renal artery embolization, blood transfusion, sepsis and vascular thrombosis. Minor complications were defined as gross haematuria, renal hematoma and arterio-venous fistula. <h3>Results</h3> Fifty-four TCRB and 256 TJRB were analysed – 69 aspirin TJRB, 68 anticoagulant TJRB and 119 no-antithrombotic TJRB. Major complications rate was 1.9% for TCRB and 2.0% for TJRB (p=1). One patient in the TJRB group suffering from catastrophic antiphospholipid syndrome (CAPS) died suddenly 6 weeks after the biopsy. No patient died of bleeding complication. One patient in the anticoagulant TJRB group required a renal artery embolization and blood transfusion. Four other patients required blood transfusion (1 in the TCRB group, 1 in the aspirin TJRB group and 2 in the anticoagulant TJRB group). Minor complications rate was 1.9% for TCRB and 7.8% for TJRB (p=0.2). Among the 256 TJRB, the rate of complication (major or minor) was higher for patients with glomerular filtration rate CKD-EPI &lt;30 mL/min (6/24 [25%]) compared to patients with GFR &gt;30 mL/min (16/232 [7%], p&lt;0.01 using the Khi-2 test). Age over 40, blood pressure &gt;140/90 mmHg, APS or positive antiphospholipid biology without APS, Prothrombin Time&lt;50%, activated Partial Thromboplastin Time ratio &gt;1.2, platelets&lt;50 G/L and biopsied kidney size were not associated with a higher rate of complications. The number of glomeruli sampled and the performance of the biopsy to establish a histologic diagnostic were similar in the 4 groups. <h3>Conclusions</h3> TJRB provides diagnostic yield and safety similar to those of TCRB. It should be considered as a first intention procedure for SLE and APS patients at risk of bleeding. <h3>Disclosure of Interest</h3> None declared
THU0169 Relationship of frailty and disease activity in patients with rheumatoid arthritis: data from the chikara study
Authors: M. Tada, Y. Yamada, K. Mandai, N. Hidaka
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Frailty is defined as degradation of physical and cognition function in elderly adult<sup>1</sup>. The characteristics of frailty include not only physical problems as co-morbidity and disability, but also mental and social problems. It is unclear of relationship between frailty and disease activity of patients with rheumatoid arthritis (RA). <h3>Objectives</h3> We investigated the relative factors about frailty in patients with RA from a prospective observational study. <h3>Methods</h3> 95 from 100 patients entered the CHIKARA study (Correlation researcH of sarcopenIa, sKeletal muscle and disease Activity in Rheumatoid Arthritis) were investigated by frailty check list (maximal score is 25). According to reported article, frailty was defined from 8 to 25 and pre-frailty was from 4 to 7, and normal was from 0 to 3. We investigated relationship of disease activity in frailty, pre-frailty and normal groups, and analysed the relative factors for frailty. <h3>Results</h3> The prevalence of frailty, pre-frailty, and normal was 19%, 39% and 42%, respectively. The character of groups indicated at table 1. Frailty group was the oldest of three groups. Disease activity sore 28 erythrocyte sedimentation rate (DAS28ESR) and matrix metalloproteinase 3 (MMP3) of frailty group was higher than those of pre-frailty and normal groups. Whereas, modified health assessment questionnaire (mHAQ) of frailty group was lower than those of pre-frailty and normal groups. Normal was 66.6% and frailty was 6.7% in remission patients. However, Normal was 13.3% and frailty was 46.7% in moderate and high disease activity patients (figure 1). The prevalence of frailty was increased with disease activity. The relative factors for frailty were age, locomotive syndrome, DAS28ESR, mHAQ, and Steinbroker class, positively and leg muscle score and grip strength, negatively by univariate analysis. Steinbroker class (odds ratio: 3.25 95% CI: 1.11–9.51, p=0.031) and mHAQ (odds ratio: 1.29, 95% CI: 1.13–1.46, p&lt;0.001) were independent relative factors by multivariate analysis. <h3>Conclusions</h3> It was revealed that frailty involved disease activity and physical function in patients with RA. Control of disease activity is important to prevent not only disease progression, but also frailty. <h3>Reference</h3> [1] Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci2001;56:M146–56. <h3>Disclosure of Interest</h3> None declared
AB1334 Evaluation of dynamics of mortality from diseases of the bone-muscular system in karakalpakstan
Authors: M. Salokhiddinov, U. Anarmetova, G. Haydarova
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Karakalpakstan is now mostly desert and is located in western Uzbekistan near the Aral Sea, in the lowest part of the Amu Darya basin. The desertification of the Aral Sea has brought a lot of dust in the air, and respiratory diseases – bone-muscular diseases – have become the largest local health problem among the population of Karakalpakstan, a region in the North Western part of Uzbekistan. <h3>Objectives</h3> To asses of the dynamics of mortality trends from diseases of bone-muscular system (BMS) in the Karakalpakstan region in 2010–2015 <h3>Methods</h3> To study mortality from BMS, databases on mortality of residents in Karakalpakstan for 2010–2015, obtained with the help of an automated mortality registration system, were used to automatically code and select the original cause of death in accordance with the rules of ICD-10. <h3>Results</h3> In the Karakalpakstan region, there has been a trend of a significant increase in mortality from BMS from 3.0 in 2010 to 5.6 per 1 00 000 in 2015 (1.9 times), with a slight decrease in the death rate from the BMS in Uzbekistan from 1.7 in 2010 to 1.6 in 2015 per 100 thousand people (the rate of decline is 5.9%). So that Decrease in the mortality rate from diseases of the musculoskeletal system in Uzbekistan from 1.7 to 1.6 per 100 thousand of population (the rate of decrease is 5.9%) and the growth of mortality rates from diseases of the musculoskeletal system was 1.9 times from 2001 to 2015 <h3>Conclusions</h3> The growth of mortality rates from musculoskeletal system diseases in the Karakalpakstan region is not related to the rates of overall mortality of the population, but is more reliable due to the use of the automated system for recording mortality, as well as training physicians to codify medical and statistical diagnoses. <h3>References</h3> [1] Wolfe F, Michaud K, Gefeller O, et al. Predicting mortality in patients with rheumatoid arthritis. Arthritis &amp; Rheumatism. 2003;48(6):1530–1542 [2] Wolfe F, Ross K, Hawley DJ, et al. The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: a study of 1141 patients. Journal of Rheumatology1993;20(12):2005–2009. <h3>Disclosure of Interest</h3> None declared
Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes
Authors: Jiri Minarik, Petra Krhovska, Tomas Jelinek, Alexandra Jungova, Martin Mistrik, Tomas Pika, Evzen Gregora, Vladimir Maisnar, Jan Straub, Ludek Pour, Lucie Brozova, Jaroslav Bacovsky, Hana Plonkova, Pavel Jindra, Petr Pavlicek, Jakub Radocha, Ivan Spicka, Martin Stork, Vlastimil Scudla, Roman Hajek
Journal: Blood (2018)
FRI0366 Primary respiratory disease in patients with systemic lupus erythematosus: data from the spanish rheumatology society lupus registry (RELESSER) cohort
Authors: J. Narvaez, H. Borrell, F. Sánchez-Alonso, I. Rúa-Figueroa, F.J. Lopez-Longo, M. Galindo, J. Calvo-Alen, A. Fernández-Nebro, A. Olivé, J.L. Andreu, R. Blanco, M. Andres, J.J. Alegre, T. Cobo-Ibañez, G. Bonilla, A. Boteanu, E. Díez-Álvarez, M. Freire, M. Gantes, P. Garcia de la Peña, R. Garcia-Vicuña, J. Hernández Beiraín, M.L. Horcada, J. Ibañez, A. Juan Mas, N. Lozano-Rivas, J.L. Marenco, I. Castelvi, C. Montilla-Morales, M. Moreno, A. Pecondon-Español, E. Ruiz Lucea, A. Sanchez-Atrio, G. Santos-Soler, F. Toyos, E. Uriarte Isacelaya, T.R. Vazquez-Rodriguez, J.M. Nolla, J.M. Pego-Reigosa
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To investigate the primary respiratory manifestations (PRM) in SLE. <h3>Methods</h3> All patients in the RELESSER cohort were retrospectively investigated for the presence of PRM <h3>Results</h3> At least one PRM was present in 11.3% (365/3215) of cases. The most common was pleurisy, occurring in 21.1% of patients, followed by ALP in 3.6%, PE in 2.9%, PPH 4%, DILD in 2%, DAH in 0.8%, and SLS in 0.8%. The variables associated with the presence of PPM are shown in the following table 1: <h3>Conclusions</h3> PPM independently contributed to a decreased survival in SLE <h3>Disclosure of Interest</h3> None declared
SAT0343 Cardiovascular disease risk in clinical subtypes of psoriatic arthritis
Authors: N. Hassan, M. Bradley, R. Davies, E. Choy
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Patients with psoriatic arthritis (PsA) have been shown to be at increased risk of developing cardiovascular disease (CVD), with one recent meta-analysis demonstrating an increased CVD risk of 43% compared to the general population. However PsA is a heterogeneous disease consisting of five different clinical subtypes. It is not known whether the risk of CVD varies between different PsA subtypes. <h3>Objectives</h3> To determine whether particular subtypes of PsA are associated with an increased risk of cardiovascular disease. <h3>Methods</h3> 114 patients with PsA attending the University Hospital of Wales were asked to complete a questionnaire about their cardiovascular risk factors. Anthropometric and biochemical measurements, including blood pressure, body mass index (BMI), C-reactive protein (CRP) and cholesterol, were also performed. Patients were grouped into one of the five PsA subtypes as described by Moll and Wright. The QRISK2 algorithm was used to determine the 10 year risk of developing CVD for each patient. Multivariate analyses using linear and logistic regression with QRISK2 score and QRISK2 score &gt;10% as dependent variables were conducted and adjusted for known cardiovascular risk factors. <h3>Results</h3> Symmetrical polyarthritis was the most common subtype, no patients had arthritis mutilans. There were no statistically significant differences between the subtypes with regards to age, gender, BMI, blood pressure, smoking status, cholesterol or CRP. Statistically significant differences were found between the subtypes using Chi-square (χ2) tests for QRISK2 score &gt;10% (p=0.031) as well as the presence of existing cardiovascular disease, diabetes mellitus and cholesterol lowering treatment (p=0.021, 0.021 and 0.037 respectively). The table 1 below lists the number of patients by subtype and these variables. <h3>Conclusions</h3> PsA patients with symmetrical polyarthritis appear to have the lowest risk of developing CVD. This subtype also had a significantly lower proportion of patients with coexisting diabetes mellitus. Patients with the distal interphalangeal (DIP) subtype are more likely to have existing CVD and be on cholesterol-lowering medications. Patients with the DIP and spinal predominant subtypes of PsA are also more likely to have a QRISK2 score of greater than 10% compared to the other PsA subtypes, suggesting they are more likely to develop CVD and may consequently need closer monitoring and management of CVD risk factors. <h3>References</h3> [1] Polachek A, Touma Z, Anderson M, Eder L. Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies. Arthritis Care Res2017Jan;69(1):67–74. [2] Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum1973;3:55–78. <h3>Disclosure of Interest</h3> None declared
AB0866 Advanced metrology in patiens with axial spondyloarthritis: lumbar or thoracic+lumbar measurements for spinal mobility assessment?
Authors: I.C. Aranda-Valera, L. Garcia-Luque, S. Alcaraz-Clariana, J.L. Garrido-Castro, I. Martinez-Sanchez, C. Gonzalez, P. Gardiner, P.M. Machado, E. Collantes
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Advanced technologies for measuring human mobility have recently emerged: motion capture, inertial measurement units (IMU) and wereable devices. Some of them are used for mobility assessment of rheumatic patients.<sup>1</sup> Certain devices analyse only lumbar mobility of the patients. Axial Spondyloarthritis (axSpA) reduces spinal mobility at all levels and not only at the lumbar level. <h3>Objectives</h3> To analyse what is the contribution of the thoracic spine to spinal mobility, and if this contribution should be taken into account in the metrological assessment of patients with axSpA. <h3>Methods</h3> 20 patients with axSpA and 20 age, BMI and sex-matched healthy subjects were recruited. An IMU sensor-based system (ViMove©) was used to measure spinal mobility. This system uses two IMU sensors and the angle between both is obtained in real time. Two tests were recorded: one with the recommended anatomical location (pelvis and L1) and another one aimed at combining lumbar +thoracic movement (pelvis and T3). Conventional metrology, radiographic structural damage (axSpA patients) and PROs were also collected. <h3>Results</h3> The table shows the results obtained for measuring only lumbar or lumbar +thoracic mobility, in both groups. The contribution of the thoracic spine is expressed in% of the total movement. Pearson correlation coefficients (only for patients) with conventional metrology (BASMI), PRO questionnaires (BASDAI, BASFI and ASQoL) and structural damage (mSASSS) scores are also presented. <h3>Conclusions</h3> Thoracic +Lumbar results reflect better the spinal mobility impairment of axSpA patients compared to lumbar spine assessments only. Compared to isolated lumbar spine assessment, the combined assessment showed better correlations with conventional metrology, disease activity, physical function, health-related quality of life and spinal structural damage. Despite this, the magnitude of the differences is not enough to reject the use of a system that only considers assessment of lumbar spinal mobility. <h3>Reference</h3> [1] Garrido-Castro JL, et al. Assessment of spinal mobility in ankylosing spondylitis using a video-based motion capture system. Man Ther. 2012Oct;17(5):422–6. <h3>Acknowledgements</h3> This study has been funded by Foreum (Foundation for Research in Rheumatology) <h3>Disclosure of Interest</h3> None declared
AB0840 Determination of serum levels of and anti-drug antibody production against tnf inhibitors in ankylosing spondylitis: testing may be useful for the assessment of compliance but not that of treatment effectiveness
Authors: K. Gulyás, A. Medelle, N. Bodnár, Z. Szekanecz, S. Szántó
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Targeted therapies, such as TNF-alpha inhibitors revolutionised the treatment of spondyloarthritides including ankylosing spondylitis (AS). <h3>Objectives</h3> To determine the correlation between serum TNF-alpha inhibitor levels of patients receiving biological therapy and concentration of anti-drug antibodies, disease activity (treatment effectiveness), age of patients and elapsed time since the onset of the diagnosis and from the initiation of the therapy. <h3>Methods</h3> Serum levels of TNF-alpha inhibitors (mg/ml) and concentration of anti-drug antibodies (AU/ml) were measured in 37 AS patients. Altogether 12 patients were treated with infliximab (IFX), 15 received adalimumab (ADA) and 10 received etanercept (ETN). Demographic data and parameters measuring disease activity (BASDAI) were also included in the analysis. <h3>Results</h3> A strong negative correlation was found between the concentration of anti-drug antibodies and drug serum levels (IFX: R<sup>2</sup>=0.833; ADA: R<sup>2</sup>=0.426; ETN: R<sup>2</sup>=0.587). On the other hand, similar correlation could not be demonstrated between serum concentrations of IFX, ADA or ETN and other factors, such as age of the patient (IFX: R<sup>2</sup>=0.050; ADA: R<sup>2</sup>=0.090; ETN: R<sup>2</sup>=0.016), BASDAI (IFX: R<sup>2</sup>=0.099; ADA: R<sup>2</sup>=0.071; ETN: R<sup>2</sup>=0.015), disease duration (IFX: R<sup>2</sup>=0.024; ADA: R<sup>2</sup> &lt;0.001; ETN: R<sup>2</sup>=0.182) and time since the initiation of therapy (IFX: R<sup>2</sup>=0.008; ADA: R<sup>2</sup>=0.052; ETN: R<sup>2</sup>=0.062). <h3>Conclusions</h3> As anti-TNF-alpha antibodies decrease the serum concentration of TNF inhibitors. In our study, drug serum levels and anti-drug antibody concentrations significantly correlated with each other. However, similarly to some other reports, drug levels did not correlate with treatment efficacy. Therefore, routine assessment of serum drug and anti-drug antibody levels should not be recommended in the everyday practice in order to determine treatment effectiveness. However, the parallel evaluation of drug and anti-drug antibody levels may be effectively used in order to determine patient compliance in the case of subcutaneously administered drugs. <h3>Disclosure of Interest</h3> None declared
Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials
Authors: Manoj Maniar, Chen Ren, Patrick S. Zbyszewski, Michael E. Petrone, Steven M. Fruchtman, David Taft
Journal: Blood (2018)
Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation
Authors: Jaap Jan Boelens, Coco de Koning, Mitchell E. Horwitz, Guillermo Sanz, Madan Jagasia, John E. Wagner, Patrick J. Stiff, Rabi Hanna, Daniela Cilloni, Stefan Nierkens
Journal: Blood (2018)
Early PET-CT to Guide Escalated Therapy in Advance Stage Hodgkin Lymphoma
Authors: Niels Moya, Antoine Machet, Thomas Systchenko, Deborah Desmier, Cécile Gruchet, Anthony Levy, Florence Sabirou, Arthur Bobin, Laura Perrichot, Celine Debiais Delpech, Catherine Cheze Le Rest, Xavier Leleu, Vincent Delwail, Stephanie Guidez
Journal: Blood (2017)
Initiating Opioid Agonist Treatment for Opioid Use Disorder in the Inpatient Setting
Authors: Amer Raheemullah, Anna Lembke
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal